Raltegravir-based regimens are effective in HIV-1 group O-infected patients

J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):e1-3. doi: 10.1097/QAI.0b013e31826327c4.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-HIV Agents / administration & dosage*
  • Antiretroviral Therapy, Highly Active / methods*
  • CD4 Lymphocyte Count
  • Female
  • Genotype
  • HIV Infections / drug therapy*
  • HIV Infections / virology*
  • HIV-1 / classification*
  • HIV-1 / genetics*
  • HIV-1 / isolation & purification
  • Humans
  • Male
  • Middle Aged
  • Pyrrolidinones / administration & dosage*
  • Raltegravir Potassium
  • Treatment Outcome
  • Viral Load

Substances

  • Anti-HIV Agents
  • Pyrrolidinones
  • Raltegravir Potassium